Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YolTech Shares Initial Data On YOLT-101 In-Vivo Base Editing for Cholesterol
Details : YOLT-101 is a next-generation in vivo base-editing therapeutic, being evaluating in the early-stage clinical trial studies for the treatment of Familial Hypercholesterolemia.
Product Name : YOLT-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SGC001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sungen’s SGC001 mAb Gets FDA Fast Track Approval as World-First Drug
Details : SGC001 is a monoclonal antibody, which is currently being evaluated for the treatment of patients suffering from acute myocardial infarction.
Product Name : SGC001
Product Type : Antibody
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : SGC001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RN0361
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rona Therapeutics Gets FDA IND Nod for Phase 2 Trial of RN0361 in Hypertriglyceridemia
Details : RN0361 is a potential best-in-class APOC3 target siRNA, which is currently being evaluated for the treatment of severe hypertriglyceridemia.
Product Name : RN0361
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : RN0361
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS
Deal Size : $145.3 million
Deal Type : Licensing Agreement
YolTech Signs Licensing Deal with Salubris For YOLT-101 in China
Details : YolTech will continue to advance the preclinical development of YOLT-101, while Salubris will be responsible for preparing and conducting clinical trials within the licensed territory.
Product Name : YOLT-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS
Deal Size : $145.3 million
Deal Type : Licensing Agreement
Lead Product(s) : RN0191
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : LongRiver Investments
Deal Size : $35.0 million
Deal Type : Series A Financing
Rona Therapeutics Raises $35M Series A+ to Advance Innovative Metabolic siRNA Pipeline
Details : The financing aims to fund the clinical development of the company's first program RN0191, a best-in-class PCSK9 siRNA program, which is being evaluated for treating Hypercholesteremia.
Product Name : RN0191
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 19, 2024
Lead Product(s) : RN0191
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : LongRiver Investments
Deal Size : $35.0 million
Deal Type : Series A Financing
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
Shanghai Argo Announces RNAi Licenses and Collaborations with Novartis
Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.
Product Name : BW-02
Product Type : Oligonucleotide
Upfront Cash : $185.0 million
July 01, 2024
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH
Details : YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for the treatment of high-risk heterozygous familial hypercholesterolemia.
Product Name : YOLT-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : YOLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SGB-3908
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Sanegene Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent and SanegeneBio Dose First Participant in IBI3016 Phase 1 Trial
Details : IBI3016 (SGB-3908) is an siRNA drug candidate targeting and reduces angiotensinogen (AGT) level in serum, in patients with essential hypertension.
Product Name : SGB-3908
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : SGB-3908
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Sanegene Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003
Details : DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-r...
Product Name : DF-003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFH312
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
Details : Preclinical data demonstrated GFH312 is able to inhibit RIPK1 kinase activity in human cells, down-regulate RIPK1 phosphorylation in animal models and curb the inflammatory response of animals' nervous system.
Product Name : GFH312
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : GFH312
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable